reports
Solid first year IONA sales; positive litigation update
Market Data: Price (p): 10.0Mkt Cap (£m): 22.8Sector: Pharmaceuticals & Biotech Strategy: Premaitha is using the latest DNA analysis technology for non-invasive prenatal screening (NIPT). Management is focused on the commercialisation of its flagship IONA test worldwide. This diagnostic technology could be developed and used also for the early detection of other diseases, such as cancer. Trading update: Premaitha has announced that 2016 sales were towards the top-end of ma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.